Bellevue Group Ag Macrogenics Inc Transaction History

Bellevue Group Ag

$4.39 Billion
Q2 2025

A detailed history of Bellevue Group Ag transactions in Macrogenics Inc stock. As of the latest transaction made, Bellevue Group Ag holds 9,919,992 shares of MGNX stock, worth $15.1 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares

9,919,992

Previous 9,929,963 0.1%

Holding current value

$15.1 Million

Previous $12.6 Million 4.82%

% of portfolio

0.27%

Previous 0.29%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.06 - $1.79 $10,569 - $17,848	-9,971 Reduced 0.1%	9,919,992 $12 Million
Q3 2024 Nov 14, 2024	SELL	$3.0 - $5.55 $37,050 - $68,542	-12,350 Reduced 0.12%	9,929,963 $32.7 Million
Q2 2024 Aug 14, 2024	SELL	$3.31 - $18.51 $77,947 - $435,891	-23,549 Reduced 0.24%	9,942,313 $42.3 Million
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $122,603 - $269,427	12,549 Added 0.13%	9,965,862 $147 Million
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $672,000 - $1.52 Million	150,000 Added 1.53%	9,953,313 $95.8 Million
Q3 2023 Nov 14, 2023	BUY	$4.48 - $6.19 $866,432 - $1.2 Million	193,400 Added 2.01%	9,803,313 $45.7 Million
Q1 2023 May 15, 2023	BUY	$4.82 - $7.24 $3.04 Million - $4.56 Million	630,000 Added 7.02%	9,609,913 $68.9 Million
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $5.53 Million - $11.5 Million	1,654,399 Added 22.58%	8,979,913 $60.3 Million
Q1 2022 May 13, 2022	SELL	$8.12 - $16.9 $10 Million - $20.9 Million	-1,234,948 Reduced 14.43%	7,325,514 $64.5 Million
Q4 2021 Feb 10, 2022	BUY	$15.91 - $21.88 $252,412 - $347,126	15,865 Added 0.19%	8,560,462 $137 Million
Q3 2021 Nov 12, 2021	BUY	$19.74 - $28.7 $23.1 Million - $33.5 Million	1,168,571 Added 15.84%	8,544,597 $179 Million
Q2 2021 Aug 12, 2021	BUY	$20.49 - $35.63 $27.6 Million - $48 Million	1,348,100 Added 22.36%	7,376,026 $198 Million
Q1 2021 May 12, 2021	BUY	$18.99 - $33.2 $2.34 Million - $4.1 Million	123,409 Added 2.09%	6,027,926 $192 Million
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $12.1 Million - $16.2 Million	622,329 Added 11.78%	5,904,517 $135 Million
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $6.91 Million - $8.85 Million	280,072 Added 5.6%	5,282,188 $133 Million
Q2 2020 Aug 13, 2020	SELL	$5.2 - $29.12 $5.81 Million - $32.5 Million	-1,117,034 Reduced 18.25%	5,002,116 $140 Million
Q1 2020 May 14, 2020	BUY	$4.28 - $12.11 $1.05 Million - $2.98 Million	245,794 Added 4.18%	6,119,150 $35.6 Million
Q4 2019 Feb 14, 2020	BUY	$7.95 - $12.27 $5.94 Million - $9.18 Million	747,792 Added 14.59%	5,873,356 $63.9 Million
Q3 2019 Nov 14, 2019	BUY	$12.44 - $17.48 $9.08 Million - $12.8 Million	730,300 Added 16.62%	5,125,564 $65.4 Million
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $52.3 Million - $71.1 Million	3,604,959 Added 456.15%	4,395,264 $74.6 Million
Q1 2019 May 15, 2019	SELL	$11.11 - $25.6 $3.07 Million - $7.08 Million	-276,688 Reduced 25.93%	790,305 $14.2 Million
Q4 2018 Feb 12, 2019	BUY	$11.75 - $21.42 $4.03 Million - $7.34 Million	342,691 Added 47.31%	1,066,993 $13.6 Million
Q3 2018 Nov 13, 2018	BUY	$19.26 - $23.46 $2.45 Million - $2.99 Million	127,389 Added 21.34%	724,302 $15.5 Million
Q2 2018 Aug 07, 2018	BUY	$19.78 - $24.67 $667,812 - $832,908	33,762 Added 6.0%	596,913 $12.3 Million
Q1 2018 May 09, 2018	SELL	$18.89 - $32.46 $23,612 - $40,575	-1,250 Reduced 0.22%	563,151 $14.2 Million
Q4 2017 Feb 14, 2018	BUY	$16.19 - $20.3 $2.12 Million - $2.66 Million	131,102 Added 30.26%	564,401 $10.7 Million
Q3 2017 Nov 13, 2017	BUY	$15.52 - $18.94 $1.81 Million - $2.21 Million	116,881 Added 36.94%	433,299 $8.01 Million
Q2 2017 Aug 14, 2017	BUY	N/A	316,418	316,418 $5.54 Million

Others Institutions Holding MGNX

# of Institutions

118

Shares Held

52.3M

Call Options Held

55.3K

Put Options Held

35.9K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $93.4M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Macrogenics Inc Transaction History